A startup's effort to translate aging biology into dermatologist-focused skincare, examining commercial strategy, physician partnerships, and market implications. It highlights commercial-clinical choices.
Key Takeaways
- Rapalogix’s latest raise is notable not simply because it brings fresh capital into the sector
- If longevity medicine is to enter the mainstream
- But perhaps the most vital bridge we have between laboratory geroscience and actual clinical practice